Diagnosis of pulmonary tuberculosis

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 3, 2013, Pages 280-288

  Lawn, Stephen D ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Diagnosis; LAM; Pulmonary; Tuberculosis; Xpert MTB RIF

Indexed keywords

LIPOARABINOMANNAN;

ANTIGEN DETECTION; BREATH ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEOGRAPHY; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LUNG TUBERCULOSIS; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SPUTUM ANALYSIS; URINALYSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; TUBERCULOSIS, PULMONARY;

EID: 84878054526     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32835f1b70     Document Type: Review

References (71)

1. World Health Organization. Global tuberculosis control report 2012. Geneva: World Health Organization; 2012. Available at: http://apps.who.int/iris/ bitstream/10665/75938/1/9789241564502-eng.pdf.
2. Lonnroth K, Jaramillo E, Williams BG, et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009; 68:2240- 2246.
3. UNITAID Secretariat. Tuberculosis diagnostic technology landscape 2012. Geneva; World Health Organization; 2012. Available at: http://www.unitaid. eu/images/marketdynamics/publications/UNITAID-Tuberculosis-Landscape-2012.pdf.
4. Pai M, Minion J, Sohn H, et al. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med 2009; 30:701-716; viii.
5. McNerney R, Maeurer M, Abubakar I, et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis 2012; 205 (Suppl. 2):S147-S158.
6. Lawn SD, Nicol MP. Xpert(R) MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 2011; 6:1067-1082.
7. WHO. Tuberculosis diagnostics automated DNA test. WHO endorsement and recommendations. Geneva: World Health Organization; 2010. Available at: http://www.who.int/tb/features-archive/xpert-factsheet.pdf.
8. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-1015.
9. Chang K, Lu W, Wang J, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 2012; 64:580-588.
10. O'Grady J, Bates M, Chilukutu L, et al. Evaluation of the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic. Clin Infect Dis 2012; 55:1171-1178.
11. Balcells ME, Garcia P, Chanqueo L, et al. Rapid molecular detection of pulmonary tuberculosis in HIV-infected patients in Santiago, Chile. Int J Tuberc Lung Dis 2012; 16:1349-1353.
12. Carriquiry G, Otero L, Gonzalez-Lagos E, et al. A diagnostic accuracy study of Xpert(R)MTB/RIF in HIV-positive patients with high clinical suspicion of pulmonary tuberculosis in Lima, Peru. PLoS One 2012; 7:e44626.
13. Yoon C, Cattamanchi A, Davis JL, et al. Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS One 2012; 7:e48599.
14. Zeka AN, Tasbakan S, Cavusoglu C. Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. J Clin Microbiol 2011; 49:4138- 4141.
15. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8:e1001067.
16. Dorman SE, Chihota VN, Lewis JJ, et al. Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. PLoS One 2012; 7:e43307.
17. Ntinginya EN, Squire SB, Millington KA, et al. Performance of the Xpert(R) MTB/RIF assay in an active case-finding strategy: a pilot study from Tanzania. Int J Tuberc Lung Dis 2012; 16:1468-1470.
18. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the XpertMTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011; 184:132-140.
19. Scott LE, McCarthy K, Gous N, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011; 8:e1001061.
20. Lawn SD, Kerkhoff AD, Vogt M, Wood R. High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay. J Acquir Immune Defic Syndr 2012; 60:289-294.
21. Peter JG, Theron G, Muchinga TE, et al. The diagnostic accuracy of urinebased Xpert MTB/RIF in HIV-infected hospitalized patients who are smearnegative or sputum scarce. PLoS One 2012; 7:e39966.
22. Blakemore R, Nabeta P, Davidow AL, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am J Respir Crit Care Med 2011; 184:1076-1084.
23. Zyl-Smit RN, Binder A, Meldau R, et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PLoS One 2011; 6:e28815.
24. Theron G, Pinto L, Peter J, et al. The use of an automated quantitative polymerase chain reaction (Xpert MTB/RIF) to predict the sputum smear status of tuberculosis patients. Clin Infect Dis 2012; 54:384- 388.
25. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 2011; 204 (Suppl. 4):S1159-S1167.
26. Lawn SD, Kerkhoff AD, Vogt M, et al. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 2012; 54:1071-1079.
27. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-1505.
28. Foundation for Innovative New Diagnostics (FIND). Negotiated prices for Xpert1 MTB/RIF and FIND country list. Geneva: FIND; 2012. Available at: http://www.finddiagnostics.org/about/what-we-do/successes/find-negotia ted-prices/xpert-mtb-rif.html.
29. Trebucq A, Enarson DA, Chiang CY, et al. Xpert(R) MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis 2011; 15: 1567-1572.
30. Kirwan DE, Cardenas MK, Gilman RH. Rapid implementation of new TB diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF? Am J Trop Med Hyg 2012; 87:197-201.
31. Evans CA. GeneXpert - a game-changer for tuberculosis control? PLoS Med 2011; 8:e1001064.
32. Lawn SD, Kerkhoff AD, Wood R. Location of Xpert(R) MTB/RIF in centralised laboratories in South Africa undermines potential impact. Int J Tuberc Lung Dis 2012; 16:701.
33. Clouse K, Page-Shipp L, Dansey H, et al. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J 2012; 102:805-807.
34. Schnippel K, Meyer-Rath G, Long L, et al. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health 2012; 17:1142-1151.
35. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011; 8:e1001120.
36. Andrews JR, Lawn SD, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS 2012; 26:987-995.
37. Abimbola TO, Marston BJ, Date AA, et al. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 60:e1-e7.
38. Winetsky DE, Negoescu DM, Demarchis EH, et al. Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern Europe: a cost-effectiveness analysis. PLoS Med 2012; 9:e1001348.
39. Seoudi N, Mitchell SL, Brown TJ, et al. Rapid molecular detection of tuberculosis and rifampicin drug resistance: retrospective analysis of a national U.K. molecular service over the last decade. Thorax 2012; 67:361-367.
40. Dorman SE, Chihota VN, Lewis JJ, et al. Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. J Clin Microbiol 2012; 50:1189-1194.
41. Crudu V, Stratan E, Romancenco E, et al. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J Clin Microbiol 2012; 50:1264-1269.
42. Barnard M, Gey van Pittius NC, van Helden PD, et al. The diagnostic performance of the Geno Type MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol 2012; 50:3712-3716.
43. Mitarai S, Okumura M, Toyota E, et al. Evaluation of a simple loop-mediated isothermal amplification test kit for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2011; 15:1211-1217.
44. George G, Mony P, Kenneth J. Comparison of the efficacies of loop-mediated isothermal amplification, fluorescence smear microscopy and culture for the diagnosis of tuberculosis. PLoS One 2011; 6:e21007.
45. Niemz A, Boyle DS. Nucleic acid testing for tuberculosis at the point-of-care in high-burden countries. Expert Rev Mol Diagn 2012; 12:687-701.
46. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis 2012; 12:103.
47. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012; 12:201-209.
48. Peter JG, Theron G, van Zyl-Smit R, et al. Diagnostic accuracy of a urine LAM strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J 2012; 40:1211-1240.
49. Minion J, Leung E, Talbot E, et al. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J 2011; 38:1398-1405.
50. Lawn SD, Edwards DJ, Kranzer K, et al. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009; 23:1875- 1880.
51. Shah M, Variava E, Holmes CB, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr 2009; 52:145-151.
52. Talbot E, Munseri P, Teixeira P, et al. Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One 2012; 7:e32876.
53. Shah M, Martinson NA, Chaisson RE, et al. Quantitative analysis of a urinebased assay for detection of lipoarabinomannan in patients with tuberculosis. J Clin Microbiol 2010; 48:2972-2974.
54. Wood R, Racow K, Bekker LG, et al. Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria. BMC Infect Dis 2012; 12:47.
55. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS 2012; 26:1635-1643.
56. Lawn SD, Harries AD, Meintjes G, et al. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2012; 26:2121-2133.
57. McNerney R, Wondafrash BA, Amena K, et al. Field test of a novel detection device for Mycobacterium tuberculosis antigen in cough. BMC Infect Dis 2010; 10:161.
58. Chambers ST, Scott-Thomas A, Epton M. Developments in novel breath tests for bacterial and fungal pulmonary infection. Curr Opin Pulm Med 2012; 18:228-232.
59. Kolk A, Hoelscher M, Maboko L, et al. Electronic-nose technology using sputum samples in diagnosis of patients with tuberculosis. J Clin Microbiol 2010; 48:4235-4238.
60. Kolk AH, van Berkel JJ, Claassens MM, et al. Breath analysis as a potential diagnostic tool for tuberculosis. Int J Tuberc Lung Dis 2012; 16:777- 782.
61. Bruins M, Rahim Z, Bos A, et al. Diagnosis of active tuberculosis by e-nose analysis of exhaled air. Tuberculosis 2012. [Epub ahead of print]
62. Hatherill M, Hanslo M, Hawkridge T, et al. Structured approaches for the screening and diagnosis of childhood tuberculosis in a high prevalence region of South Africa. Bull World Health Organ 2010; 88:312-320.
63. Whittaker E, Zar HJ. Promising directions in the diagnosis of childhood tuberculosis. Expert Rev Respir Med 2012; 6:385-395.
64. Moore HA, Apolles P, de Villiers PJ, Zar HJ. Sputum induction for microbiological diagnosis of childhood pulmonary tuberculosis in a community setting. Int J Tuberc Lung Dis 2011; 15:1185-1190.
65. Zar HJ, Workman L, Isaacs W, et al. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis 2012; 55:1088-1095.
66. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the XpertMTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011; 11:819-824.
67. Rachow A, Clowes P, Saathoff E, et al. Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study. Clin Infect Dis 2012; 54:1388-1396.
68. Bates M, O'Grady J, Maeurer M, et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis 2012; 13:36-42.
69. Tortoli E, Russo C, Piersimoni C, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012; 40:442- 447.
70. Lawn SD, Zumla AI. Diagnosis of extrapulmonary tuberculosis using the Xpert((R)) MTB/RIF assay. Expert Rev Anti Infect Ther 2012; 10:631-635.
71. Walters E, Gie RP, Hesseling AC, et al. Rapid diagnosis of pediatric intrathoracic tuberculosis from stool samples using the Xpert MTB/RIF assay: a pilot study. Pediatr Infect Dis J 2012; 31:1316.